Form 8-K

8-K — Cigna Group

Accession: 0001140361-26-038056

Filed: 2026-09-30

Period: 2026-09-30

CIK: 0001739940

SIC: 6324 (HOSPITAL & MEDICAL SERVICE PLANS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ef20082869_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20082869_ex99-1.htm)

GRAPHIC (image0.jpg)

GRAPHIC (image00001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20082869_8k.htm · Sequence: 1

false0001739940NYSE00017399402026-09-302026-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 30, 2026

The Cigna Group

(Exact name of registrant as specified in its charter)

Delaware

001-38769

82-4991898

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

900 Cottage Grove Road

Bloomfield, Connecticut 06002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (860) 226-6000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.01

New York Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the

Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

Outlook and Investor Day Information

On September 30, 2026, The Cigna Group (referred to as the “Company,” “we,” “us” or “our”) issued a press

release noting that the Company will host its Investor Day, both in person and virtually, beginning at approximately 8:30 a.m. Eastern Time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”). During

Investor Day, as well as in meetings with investors and analysts over the next several weeks, Company officials expect to reaffirm the following full year 2026 outlook:

•

consolidated adjusted revenues of approximately $280 billion,

•

consolidated adjusted income from operations on a per share basis (“adjusted earnings per share” or “adjusted EPS”) of at least $30.45,

•

Evernorth Health Services adjusted income from operations of at least $6.9 billion,

•

Cigna Healthcare adjusted income from operations of at least $4.55 billion, and

•

Cigna Healthcare medical care ratio of 83.7% to 84.7%.

Company officials also expect to provide a long-term average annual adjusted EPS growth target of 10-14%.

The Company previously discussed its full year 2026 outlook in its press release dated July 30, 2026 and during the related investor conference call. The press release

and the conference call transcript are available on the Investor Relations page of the Company’s website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak only as of the date they were made.

The Investor Day presentations are expected to begin on September 30, 2026 at approximately 8:30 a.m. Eastern Time and conclude by 12:30 p.m. Eastern Time. Investors and

analysts are invited to listen to the presentation free over the Internet via webcast by visiting https://www.thecignagroupinvestorday.com. The Investor Relations section of the Company’s website will also contain materials used

during and relating to the Investor Day presentations, including definitions of certain metrics not determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and reconciliations of certain

historic non-GAAP metrics to the most directly comparable GAAP measures.

Definitions and Financial Information

Adjusted revenues is used by the Company’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total

revenues excluding the following adjustments: special items and the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that

management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future

underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues.

Adjusted income (loss) from operations is a principal financial measure of profitability used by the Company’s management because it presents the underlying results of

operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income (or income before taxes less

pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Company’s share of certain investment results of its

joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due

to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in

accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income or adjusted revenues to total revenues on a

forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various

factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

The Cigna Healthcare medical care ratio represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or

experience-rated funding arrangements. Changes in percentages may be expressed in basis points.

The Company’s outlook excludes the potential effects of any business combinations that may occur after the date of this Report. The Company’s outlook includes the

potential effects of expected future share repurchases and anticipated 2026 dividends.

The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination

that the declaration of dividends remains in the best interests of the Company and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of

operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of

capital. The share repurchase program may be affected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated

transactions. The program may be suspended or discontinued at any time.

This information, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the

Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Report, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.

Description

99.1

Press release dated September 30, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL).

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Report, and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking

statements may include, among others, statements concerning our projected adjusted revenue for 2026; projected adjusted income from operations for 2026 on a per share and segment basis, projected medical care ratio for 2026; projected adjusted

earnings per share outlook on a long-term basis; projected capital deployment, including share repurchases and future dividends, including projected shareholder dividends for 2026; and other statements regarding the Company’s future beliefs,

expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate,"

"predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or

implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result

in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly

changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain

relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to

expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential

liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who

participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy,

security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly

maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine

learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect

our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative

to expectations; which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on

employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the

future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of

www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions

that are difficult to predict or quantify. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

THE CIGNA GROUP

Date: September 30, 2026

By:

/s/ Ann M. Dennison

Ann M. Dennison

Executive Vice President and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20082869_ex99-1.htm · Sequence: 2

Exhibit 99.1

The Cigna Group Hosts 2026 Investor Day;

Introduces “Lead to One” to Drive Durable Growth

Through Complex Care Leadership and Differentiated Capabilities

•

Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned where health care costs are concentrating

with multiple avenues for growth

•

Announces “Lead to One” vision, unifying all colleagues around delivering personalization at scale to improve affordability and the patient experience

•

Distinct, industry-leading capabilities in complex care, powered by clinical expertise, data, technology and AI

•

Announces $3B multi-year modernization and productivity initiatives to fuel performance

•

Reaffirms 2026 full-year financial guidance and provides long-term financial growth target of 10-14% adjusted EPS CAGR through 2030

BLOOMFIELD, Conn., Sept. 30, 2026 – Today, at its

Investor Day, The Cigna Group (NYSE: CI) will outline its strategy to improve affordability and personalization across the health care continuum. Enterprise leaders will detail how the Company’s deliberately shaped portfolio, differentiated

leadership in complex care, and disciplined execution position it to deliver durable growth, robust operating cash flow, and enhanced shareholder returns.

“We are proud to announce ‘Lead to One,’ our vision for the future of healthcare through personalization at scale. This unifies direction for our enterprise and positions

The Cigna Group for continued success as we work to improve the health of the diverse range of customers we serve,” said Brian Evanko, President and Chief Executive Officer of The Cigna Group. “We are uniquely positioned in the fastest-growing

areas of health care, with a distinct ability to serve patients with complex needs through the combined capabilities of our Evernorth Health Services and Cigna Healthcare businesses. By building on our growth platforms, scaling our differentiated

capabilities, and executing with discipline, we are well positioned to deliver durable earnings growth, create long-term shareholder value, and improve affordability and outcomes for those we are privileged to serve.”

Introduces “Lead to One” Vision to Drive Durable Growth

The Cigna Group is focused on transforming health care by improving affordability and delivering personalization for all customers across the care continuum. Lead to One

is delivered through the strategic growth framework leaders will outline today:

•

Deliver core growth: Build on the strong

foundation of a deliberately shaped portfolio — including Cigna Healthcare and Evernorth’s Specialty & Care Services and Pharmacy Benefit Services — to drive growth.

•

Leverage distinct capabilities: Apply

industry-leading complex care capabilities, enabled by clinical expertise, data, technology and AI.

•

Execute with discipline: Maintain a clear vision, consistent execution, operational excellence, a culture of innovation and disciplined capital stewardship.

Deliver core growth

The Cigna Group's businesses are connected through shared clinical expertise, data, customer relationships, and distribution capabilities, creating multiple avenues for

growth and value creation. This deliberately built foundation is aligned to attractive, growing segments of health care where the Company possesses meaningful scale, differentiated capabilities, and opportunities for continued expansion.

Leverage distinct capabilities

Complex care is rarely defined by a single diagnosis, medication or episode of care. Patients with complex needs often require support across multiple conditions,

specialty and traditional medications, behavioral health, primary and specialty care, and ongoing care navigation. The Cigna Group's advantage comes from its ability to engage patients across more of that journey than most organizations, creating

visibility into the factors that influence outcomes, affordability and experience. Supporting these patients requires a unique breadth of capabilities, and The Cigna Group's growth platforms work together to understand, anticipate and manage

clinical complexity:

•

Evernorth Specialty & Care Services:

Supports more than one million patients with complex conditions and delivers more than 8 million prescriptions annually, combining deep clinical expertise, nationwide provider and distribution capabilities, and personalized support

models that improve access, adherence, and outcomes. This combination has established Evernorth as a trusted partner to patients, providers, health systems, and drug manufacturers.

•

Cigna Healthcare: Delivers more

personalized and proactive experiences across the full spectrum of patient requirements, from identifying emerging oncology needs earlier to providing AI-enabled navigation and advocacy support.

•

Evernorth Pharmacy Benefit Services: Integrates pharmacy benefits, clinical insights, and supply chain expertise to improve affordability, support better adherence, and drive better outcomes at scale.

Together, these capabilities enable The Cigna Group to identify risk earlier, connect fragmented information across the health care system, and intervene before

higher-cost events occur. This ability to understand and manage complexity creates a meaningful advantage in affordability, personalization and outcomes, while positioning the Company to capture a growing share of one of health care's largest and

fastest-growing segments.

Evanko continued, “The capabilities that make us a leader in complex care are also being applied to improve how health care is experienced across the broader population.

By bringing together data, clinical expertise and AI through our health intelligence engine, we can identify needs earlier, personalize support and help lower the total cost of care. As we continue to scale these capabilities, we will create value

for customers, clients and shareholders alike through better outcomes, lower costs and a more connected health care experience.”

As part of its commitment to supporting people living with complex conditions, The Cigna Group Foundation is announcing a new $10.5 million, three-year grant program to

expand community support for patients and caregivers and help address non-clinical barriers to treatment. The program will focus on strengthening the services and support systems that help patients start, stay on and benefit from treatment,

including care navigation, education, peer support, mental health resources and assistance with essential social needs.

Execute with discipline

The Cigna Group will continue to fuel sustainable growth through operational excellence, expense discipline, and capital flexibility enabled by the Company’s

capital-light model.

Reaffirms 2026 guidance and provides 2030 financial targets

The Cigna Group reaffirms its 2026 financial guidance:

•

Consolidated Adjusted Revenues of ~$280 billion

•

Consolidated Adjusted EPS of at least $30.45

•

Evernorth Health Services pre-tax adjusted income from operations of at least $6.90 billion

•

Cigna Healthcare pre-tax adjusted income from operations of at least $4.55 billion

•

Medical care ratio of 83.7% to 84.7%

The Cigna Group provides 2026 – 2030 financial targets:

(All financial targets are through year end 2030 unless otherwise noted)

•

10-14% Adjusted EPS CAGR

•

~$50 billion in cumulative operating cash flow

As part of its Lead to One direction, The Cigna Group is announcing a new $3 billion multi-year series of modernization and productivity initiatives to support growth and

financial performance. The initiatives will focus on modernizing processes and streamlining workflows, empowering colleagues with AI-enabled insights and tools to drive greater effectiveness, along with driving disciplined supplier and vendor

management.

“We are building on a proven track record of delivering consistent and differentiated adjusted EPS growth through disciplined execution,” said Ann Dennison, Executive

Vice President and Chief Financial Officer of The Cigna Group. “Our long-term growth targets are supported by our clear growth pillars, distinct capabilities, and our new multi-year modernization and productivity initiatives, which will self-fund

and fuel our performance. We are positioned to deliver attractive, sustainable growth, robust operating cash flow, and enhanced shareholder returns.”

Webcast information

The event will begin at 8:30 a.m. ET. A live webcast of the presentation will be available at https://www.thecignagroupinvestorday.com.

To listen to this presentation live on the Internet, visit https://www.thecignagroupinvestorday.com at least 15 minutes prior to the presentation to download and install

any necessary audio software.

About The Cigna Group

The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly

challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in

more than 30 markets and jurisdictions and has over 180 million customer relationships around the world. Learn more at thecignagroup.com

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based

on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted

revenue for 2026; projected adjusted income from operations for 2026 on a segment basis, projected adjusted earnings per share and earnings per share growth rate for 2026 and future periods for The Cigna Group, Evernorth Health Services (including

Pharmacy Benefit Services and Specialty & Care Services) and Cigna Healthcare; projected medical care ratio for 2026; projected cash flow from operations; future financial or operating performance, including our ability to improve the health

and vitality of those we serve; our market opportunities; economic, regulatory or competitive environments; future growth (including growth of Evernorth Health Services and Cigna Healthcare), business strategy, and strategic or operational

initiatives, including our modernization and productivity initiatives, and ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; our prospects for growth in the

coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as

"believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or

managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in

government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data

laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our

information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence

on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational

operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations;

which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics,

stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk

related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You

should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict

or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

Notes

Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Cigna Group defines adjusted revenues as

total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are

matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or

future underlying performance of the business. Adjusted revenues are not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues.

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results

of operations of The Cigna Group’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income (or income before taxes

less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain investment results

of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring

operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not

determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income or adjusted revenues to total revenues on a

factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

The Cigna Healthcare medical care ratio represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or

experience-rated funding arrangements. Changes in percentages may be expressed in basis points.

The Cigna Group’s outlook excludes the potential effects of any business combinations that may occur after the date of this press release. The Cigna Group’s outlook

includes the potential effects of expected future share repurchases and anticipated 2026 dividends.

The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination

that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on The Cigna Group’s financial position,

results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of

transactions. The program may be suspended or discontinued at any time.

Investor Relations Contact

Ralph Giacobbe

1 (860) 787-7968

Ralph.Giacobbe@TheCignaGroup.com

Media Contact

Justine Sessions

1 (860) 810-6523

Justine.Sessions@Evernorth.com

GRAPHIC

Filename: image0.jpg · Sequence: 6

Binary file (50944 bytes)

Download image0.jpg

GRAPHIC

Filename: image00001.jpg · Sequence: 7

Binary file (4432 bytes)

Download image00001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Document and Entity Information

Sep. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 30, 2026

Entity File Number

001-38769

Entity Registrant Name

The Cigna Group

Entity Central Index Key

0001739940

Entity Incorporation, State or Country Code

Entity Tax Identification Number

82-4991898

Entity Address, Address Line One

900 Cottage Grove Road

Entity Address, City or Town

Bloomfield

Entity Address, State or Province

Entity Address, Postal Zip Code

06002

City Area Code

860

Local Phone Number

226-6000

Title of 12(b) Security

Common Stock, Par Value $0.01

Trading Symbol

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration